跳到正文
原文
Endpoints News 生物医药· Kyle LaHucik·· 2026-10-19AI 评分18

TriGemX Bio 拟通过 SPAC 上市,推动其偏头痛治疗候选药物商业化

TriGemX Bio is going public through SPAC to get its migraine prospect to market

AI 导读

药物开发公司 TriGemX Bio 计划通过特殊目的收购公司(SPAC)实现上市,以便将其在研的偏头痛候选药物推向市场。在注册制 IPO 热度下降的背景下,TriGemX Bio 选择这一路径以加速推进其偏头痛药物的开发进程。

正文

The stock mar­ket will soon wel­come an­oth­er drug de­vel­op­er through a back­door route that has been fall­en out of fa­vor now that tra­di­tion­al IPOs are …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news